Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

NCT05917860 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER_GOV

Sponsor class

Conditions

Localized Prostate Carcinoma
Castration-Naive Prostate Cancer
Intermediate Risk Prostate Cancer
Prostate Cancer

Interventions

DRUG: Degarelix
DEVICE: MRI-guided transurethral ultrasound ablation (TULSA)

Sponsor

Turku University Hospital